SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred “Freddie” Bowie, Jr., Ph.D., as vice president, corporate and business development. In this role, Dr. Bowie will lead the company’s strategic planning process and be responsible for identifying, evaluating and executing technology and business partnerships, licensing and acquisitions as well as managing biopharmaceutical collaborations to help drive long-term profitable growth for Veracyte.
“I am thrilled to welcome Freddie to the Veracyte team,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “As an accomplished executive with a strong scientific background, Freddie brings more than 10 years of strategic corporate and business development experience to our company. His broad skillset, which spans corporate strategy, business planning, alliance management and business operations, will be instrumental in helping us achieve our strategic vision.”
Prior to joining Veracyte, Dr. Bowie led strategic planning, corporate development and competitive intelligence at Foundation Medicine, a wholly owned subsidiary of Roche. He also served in corporate and business development positions of increasing responsibility at Tecan Group and Danaher Corporation. Dr. Bowie began his career in management consulting at The Boston Consulting Group where he advised clients in the pharmaceutical, biotechnology and life sciences tools industries.
Dr. Bowie received his B.S. in chemistry from Davidson College and holds a Ph.D. in synthetic organic chemistry from the University of California, Berkeley. He also completed a National Institute of Health fellowship at Harvard Medical School’s Institute of Chemistry and Chemical Biology.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks of Veracyte, Inc.